7th International CAA Conference

Welcome to the 7th International Cerebral Amyloid Angiopathy Conference. We have crafted a program that features cutting-edge research, translational ideas for clinical trials, and new knowledge on prevention and treatment of manifestations of CAA such as hemorrhagic stroke.

Eric Smith, MD, MPH
Steven Greenberg M.D. Ph.D.
Mark van Buchem MD, PhD

Message from the Chair

Welcome to the 7th International Cerebral Amyloid Angiopathy Conference. We have crafted a program that features cutting-edge research, translational ideas for clinical trials, and new knowledge on prevention and treatment of manifestations of CAA such as hemorrhagic stroke.

Our field of CAA research is being transformed by an expanding array of CAA biomarkers, better radio-pathological correlation, new model systems, and increasing therapeutic options for trials. Attend the Conference to share your own work on CAA, learn about new research and techniques, and gather information on diagnosis and treatment to help your clinical practice. The Conference covers all aspects of CAA research including molecular, tissue- or animal-based, human subject research, and clinical trails. Attendees include basic scientists, clinicians, and clinical researchers.

The 2020 Conference will be held in Banff, a resort town in the specular Canadian Rocky Mountains. Banff is accessed by Calgary International Airport, with direct connections to Frankfurt, Amsterdam, London Heathrow, Paris, Los Angeles, San Francisco, and Tokyo, among others.

We hope to see you in Banff on October 1-3, 2020.

Warmest regards,


Eric Smith, MD, MPH

Professor of Neurology, University of Calgary

Chair, 7th International CAA Conference Organizing Committee

Preliminary Program

****latest news****

Abstract submission will open April 1, 2020. Top ranking abstracts will be presented orally at the Conference.

7th International CAA Conference – Preliminary Program

Day 1 Thursday October 1


Opening Remarks and Keynote Lecture



Cerebral Amyloid Angiopathy as a Transmissable Proteinopathy


Iatrogenic CAA: An Emerging Clinical Phenomenon


Acquired CAA – Hypotheses for Mechanisms of Seeding


Experimental Evidence for Amyloid-beta Transmission from Animal Studies


Oral Abstract Presentations



New Therapeutic Strategies for CAA


RNA Inhibition Therapies


Beta-amyloid lowering therapies for CAA


Minocycline as a Therapeutic Agent for CAA


Oral Abstract Presentations



Poster Tours



Beta-Amyloid Clearance via Perivascular and Other Drainage Routes


Vasomotion in Awake Mice and During Sleep


Perivascular Spaces as a Pathway for Amyloid Clearance


Imaging CSF and ISF Pulsatility with High-field MRI in Humans


Oral Abstract Presentations




Day 2 Friday October 2


New Biomarkers of CAA


Biofluid Biomarkers


Amyloid and Tau PET Imaging


Version 2.0 of the Boston Criteria


Oral Abstract Presentations



Designing Trials for Hereditary and Non-hereditary CAA


Biomarker Evolution in Presymptomatic HCHWA-D Mutation Carriers


Trial Readiness in HCWHA-D Mutation Carriers: Australian and Dutch Experience


Design Considerations for Trials of CAA


Panel Discussion



Poster Tours



Beyond the Boston criteria: is “Pure” CAA a Useful Concept in Non-ICH Cohorts?


CAA in People With Late-onset Cognitive decline


CAA in Ischaemic Stroke and TIA Cohorts 


CAA in Convexity Subarachnoid Hemorrhages


Oral Abstract Presentations




Day 3 Saturday October 3


Microvessels, Voxels, and Bleeds


Microvascular architecture in relation to blood flow


Imaging the neurovascular unit response to microbleed


High resolution MRI of microvessel structure/function


Oral Abstract Presentations



Managing Thromboembolic Diseases in CAA


Managing Atrial Fibrillation When CAA is Present


Non-Pharmacologic Approaches to Managing Atrial Fibrillation in CAA


Antiplatelet Therapy After ICH


Animal and Tissue Models of Vascular Risk Factors and CAA


Panel Discussion



Closing Remarks 


Scientific Program Committee

Information on Banff and surroundings

Banff is a town within Banff National Park in Alberta, Canada. It is located in Alberta’s Rockies along the Trans-Canada Highway, approximately 126 km (78 mi) west of Calgary and 58 km (36 mi) east of Lake Louise. At 1,400 to 1,630 m (4,590 to 5,350 ft) above sea level,[4] Banff is the community with the second highest elevation in Alberta, after Lake Louise. 

There are a number of popular mountains located immediately adjacent to the townsite which include Mount Rundle(2,949 m or 9,675 ft); Cascade Mountain (2,998 m or 9,836 ft); and Mount Norquay (2,134 m or 7,001 ft). Mount Norquay has a ski slope as well as mountain biking trails on the Stoney Squaw portion. A popular tourist attraction, the Banff Gondola, is available to ascend Sulphur Mountain (2,281 m or 7,484 ft) where a boardwalk (Banff Skywalk) beginning from the upper terminal takes visitors to Sanson Peak. Sulphur Mountain is also the location of one of Banff’s most popular attractions, the Banff Upper Hot Springs. 

Lake Minnewanka located six minutes north of the townsite is a very popular day use area with a variety of activities. Mountain biking, hiking and fishing are all activities allowed in this part of the park. A very popular Lake Cruise, motor boat rentals and a small food concession are available at the marina. 

Tunnel Mountain (formerly known as Sleeping Buffalo Mountain) (1,690 m or 5,545 ft) is situated within the townsite and is very popular for quick hikes; one can reach the summit in less than half an hour. It was named Tunnel Mountain because surveyors initially wanted to make a tunnel for the Canadian Pacific Railway right through the mountain, instead of following the Bow River Valley. Located on the side of Tunnel Mountain is the Banff Centre for Arts and Creativity, which hosts a number of events including outdoor concerts, dance, opera and theatre. 

Banff is home to the well-known Banff World Television Festival, Banff Mountain Film Festival, Rocky Mountain Music Festival and Bike Fest. The city is also the starting point of the 4,417 km (2,745 mi) Great Divide Mountain Bike Route, which terminates at Antelope Wells, New Mexico in the United States. 

Interesting sites:




registration and room reservation desk

desk will open soon


Conference and room reservations at Banff Centre for Arts and Creativity




Banff Organizing Committee 2020